Global economic growth concerns due to the Middle East conflict and IMF's downgraded forecasts may lead to reduced investor confidence in riskier assets like clinical-stage biotechnology companies, impacting their ability to raise capital. [cite: *context*]

Inflationary pressures, indirectly fueled by rising oil prices from the Middle East conflict, could increase R&D and operational costs for Alto Neuroscience and influence interest rate policies, affecting financing costs. [cite: *context*]

While the strong US jobs report suggests a healthy domestic economy, investor sentiment for the biotech sector, particularly clinical-stage firms, is heavily influenced by specific market appetite for innovation and risk, as well as the availability of specialized funding, which could be sensitive to overall macro uncertainty. [cite: *context*]